## CIBMTR Corporate Membership Level

Access to database for simple analyses by the CIBMTR Information Resource Service  
*(Please request data via the online CIBMTR Corporate Member Information Request Form)*

### Corporate Executive  
($75,000)

<table>
<thead>
<tr>
<th>Variables:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Source: CRF</strong></td>
</tr>
</tbody>
</table>
| All Leader-level variables  
Disease-specific pre-HCT variables  
*This level of membership allows for additional variable, the potential for more outcomes, and Scientific or Statistical consultation.  
*Outcomes: Relapse, Infection, and TRM are not included within Corporate Membership |

### Corporate Leaders  
($60,000)

<table>
<thead>
<tr>
<th>Variables:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Source: CRF</strong></td>
</tr>
</tbody>
</table>
| All Patron-level variables  
Disease-specific pre-HCT variables |

### Corporate Patrons  
($30,000)

<table>
<thead>
<tr>
<th>Variables:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Source: TED</strong></td>
</tr>
</tbody>
</table>
| All Sponsor-level variables  
Comorbidity index*  
Disease status prior to HCT  
Conditioning intensity  
Conditioning regimen  
Donor age  
D-R sex match  
D-R CMV match  
GVHD prophylaxis |

### Corporate Sponsors  
($15,000)

<table>
<thead>
<tr>
<th>Variables:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Source: TED</strong></td>
</tr>
</tbody>
</table>
| Number of centers  
Patient age at HCT  
Patient gender  
Patient race  
Patient ethnicity  
Karnofsky/Lansky score  
Disease  
Sub-disease  
Type of donor  
Graft source  
Time from DX to HCT  
Year of HCT  
Median FU of survivors |

### Outcomes:

<table>
<thead>
<tr>
<th>Overall Survival plus</th>
<th>Overall Survival</th>
<th>Overall Survival</th>
<th>None</th>
</tr>
</thead>
</table>

### Description of Analysis:

Descriptive summary of the population.  
•Data will be presented by patient subgroups and predefined categories of the pre-HCT variables of interest.  
•Maximum number of tables for sub-groups (if applicable): 2  
•Analysis of overall survival will be provided as a probability (confidence interval) at specific time points (generally and if applicable: @1y, @3y, @5y).

*Available for patients transplanted after 2007.  
**Rare diseases are not included within Corporate Membership.  
***Information will be provided in aggregate form as reference in the sample table.